What The Study Did: This economic evaluation estimates the budget impact and affordability of a gene therapy for severe sickle cell disease from the perspective of U.S. Medicaid programs with the highest prevalence of sickle cell disease.
Authors: Patrick DeMartino, M.D., of Oregon Health & Science University in Portland, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamapediatrics.2020.7140)
Editor's Note: The article includes conflict of interest disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
###
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2020.7140?guestAccessKey=eafaf224-0b11-42c0-888e-8b3555ec83fd&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=032221
JAMA Pediatrics